Alnylam Pharmaceuticals (ALNY) Rating Reiterated by Piper Jaffray Companies

Piper Jaffray Companies reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report published on Sunday morning. The brokerage currently has a $182.00 target price on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other reports. Credit Suisse Group raised their target price on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an outperform rating in a research note on Friday, November 3rd. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a buy rating and a $240.00 target price on the stock. Nomura started coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 14th. They issued a reduce rating and a $56.00 target price on the stock. Chardan Capital reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research note on Monday, September 11th. Finally, Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a buy rating to a conviction-buy rating in a research note on Friday, December 15th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $121.20.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down $1.44 on Friday, reaching $129.31. 132,113 shares of the company were exchanged, compared to its average volume of 755,333. The stock has a market capitalization of $12,710.00, a P/E ratio of -24.63 and a beta of 2.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The company had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.21) earnings per share. research analysts anticipate that Alnylam Pharmaceuticals will post -5.21 EPS for the current year.

In other news, SVP Laurie Keating sold 6,249 shares of the firm’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the transaction, the executive vice president now owns 45,201 shares in the company, valued at approximately $5,490,113.46. The disclosure for this sale can be found here. Insiders sold 274,075 shares of company stock worth $35,356,089 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. FMR LLC boosted its holdings in Alnylam Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after acquiring an additional 815,270 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 13.4% in the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after acquiring an additional 759,295 shares in the last quarter. BlackRock Inc. boosted its holdings in Alnylam Pharmaceuticals by 9.3% in the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after acquiring an additional 441,957 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 69.7% in the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after acquiring an additional 445,600 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Alnylam Pharmaceuticals by 25.3% in the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after acquiring an additional 158,288 shares in the last quarter. Hedge funds and other institutional investors own 88.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Rating Reiterated by Piper Jaffray Companies” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/10/alnylam-pharmaceuticals-alny-rating-reiterated-by-piper-jaffray-companies.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

What are top analysts saying about Alnylam Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alnylam Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit